CDT — CDT Equity Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1896212 ·
Last close
$0.08
Market Cap
$1.04M
52W High
$1778.00
52W Low
$0.07
ADV30
6,395,582
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,002,000 | -4,641,000 | 126,708,000 | 747,000 | 23,615,000 |
| Mar 2026 | 0 | — | -3,656,000 | -4,063,000 | 127,087,000 | 97,000 | 21,636,000 |
| Dec 2025 | 0 | — | -21,156,000 | -21,325,000 | 5,650,000 | 1,509,000 | 12,820,000 |
| Sep 2025 | 0 | — | -6,936,000 | -7,118,000 | 8,552,000 | 3,838,000 | 4,274,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,520,000
Investing CF
$-404,000
Financing CF
$11,982,000
CapEx
$-2,403,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-23379.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,388,000
Inventory
—
Receivables
$146,000
ST Investments
—
EBIT TTM
$-38,341,000
Pretax Income TTM
$-38,533,000
Interest Exp TTM
$192,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,660,000 | -39,224,000 | 5,650,000 | 12,820,000 | -7,170,000 | -15,555,000 |
| Dec 2024 | 0 | -15,105,000 | -17,802,000 | 4,193,000 | 10,986,000 | -6,793,000 | -9,682,000 |
| Dec 2023 | 0 | -5,262,000 | -535,000 | 7,224,000 | 7,681,000 | -457,000 | -7,725,000 |
| Dec 2022 | 0 | -3,160,000 | -4,887,000 | 5,000 | 10,094,000 | -10,089,000 | -2,266,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVFM | Evofem Biosciences, Inc. | $1.06M | $0.01 | — |
| SKVI | SKINVISIBLE, INC. | $1.09M | $0.20 | — |
| GSAC | GELSTAT CORP | $1.12M | $0.00 | — |
| CMND | Clearmind Medicine Inc. | $1.17M | $0.79 | — |
| PPCB | Propanc Biopharma, Inc. | $1.22M | $0.53 | — |
News headlines (Yahoo Finance, 1h cache)
CDT Equity Inc. Announces Reverse Stock Split
2026-09-25 12:10 · Yahoo
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
2026-09-18 10:30 · Yahoo
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
2026-09-02 09:00 · Yahoo
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
2026-08-28 09:00 · Yahoo
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
2026-07-20 12:30 · Yahoo
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
2026-06-26 12:30 · Yahoo
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
2026-06-18 12:30 · Yahoo
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
2026-05-11 20:01 · Yahoo
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
2026-05-07 12:30 · Yahoo
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
2026-05-06 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.